EFPIA：2025年欧洲制药工业联盟主题分析：累积立法影响报告（英文版）

The regulatory inconsistencies within the EU and globally, as well as complex compliance requirements, may erode Europe’s pharmaceutical competitiveness. Divergent EU standards could deter investment, especially in R&D and innovation. Regulatory changes risk disrupting the supply chain and patient access to medicines if certain chemicals or processes are restricted without suitable alternatives. This could lead to shortages of essential medicines. Furthermore, new mandates for environment